Pharmacokinetics-based safety evaluation in half-dose verteporfin photodynamic therapy

Hyeong Min Kim,Hyuncheol Kim,Jae Yong Chung,Se Joon Woo

DOI: https://doi.org/10.1159/000541619

2024-09-26

Ophthalmic Research

Abstract:Introduction: This study was conducted to assess the systemic pharmacokinetic profiles of half-dose verteporfin photodynamic therapy (PDT) using concentration data from a previous clinical trial, and to subsequently suggest the safety precaution guidelines. Methods: Coefficients for the bi-exponential model were obtained from published data on post-infusion plasma verteporfin concentrations within a period of 0.17–4 h. Using the extrapolative forecasting method, we plotted the 48 h post-verteporfin plasma concentration model. The time required to achieve a comparable level of verteporfin 48 h after a conventional -dose (6 mg/m2 body surface area, BSA) infusion was calculated for a half-dose infusion (3 mg/m2 BSA). Results: At 24 and 48 hours post-verteporfin infusion, the plasma concentration following the conventional dose was 1.28 × 10−4 μg/mL and 5.06 × 10−8 μg/mL, compared to 3.57 × 10−5 μg/mL and 7.54 × 10−9 μg/mL for the half-dose PDT, representing concentrations that were 3.6 times and 6.7 times higher, respectively. The estimated time required to attain the same level of verteporfin 48 h after a conventional -dose was calculated as 42 h post- half-dose PDT. Conclusions: The study results of this study indicate that it is advisable to take necessary precautionary measures should be taken to avoid sunlight following both half and conventional doses of PDT. Nevertheless, given the substantially higher plasma concentration levels associated with conventional-dose PDT as compared withto the half-dose, systemic safety should be given duecarefully consideredation whenwhile administering conventional-dose PDT.

ophthalmology